GlassScriptPhysician profile
Martin Glaves
NPI 1578911590
$4,802.02
in general payments reported to CMS, 2019-2025
32 companies · $851 in 2025
The $851 reported for 2025 was more than what 83% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $224 · 2020: $538 · 2021: $765 · 2022: $674 · 2023: $866 · 2024: $883 · 2025: $851.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,600.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,599.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,113.65 | 2020-2025 | |
| Novo Nordisk INC | $552.76 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $475.90 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $454.53 | 2020-2025 | Farxiga, Airsupra, Breztri |
| Glaxosmithkline, LLC. | $418.50 | 2020-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Lilly USA, LLC | $247.21 | 2020-2025 | Zepbound, Mounjaro, Jardiance |
| Novartis Pharmaceuticals Corporation | $157.25 | 2021-2025 | |
| Allergan, INC. | $156.34 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $131.06 | 2020-2025 | Xifaxan, Trulance |
| Merck Sharp & Dohme LLC | $109.05 | 2020-2022 | |
| Astellas Pharma US INC | $105.64 | 2020-2024 | Veozah, Myrbetriq |
| Biohaven Pharmaceutical Holding Company LTD. | $101.07 | 2022 | |
| Exact Sciences Corporation | $91.15 | 2023-2025 | Cologuard Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $85.64 | 2022-2024 | |
| Biohaven Pharmaceuticals, INC. | $80.81 | 2021 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $58.39 | 2019-2025 | Trintellix |
| E.R. Squibb & Sons, L.L.C. | $54.88 | 2021-2022 | |
| Eisai INC. | $51.59 | 2021 | |
| Averitas Pharma INC. | $46.07 | 2023-2025 | Qutenza |
| Amgen INC. | $43.40 | 2022-2023 | Prolia, Evenity |
| Pharmacosmos Therapeutics INC. | $34.17 | 2023 | Monoferric |
| Corium, LLC | $31.20 | 2023 | Azstarys |
| Sanofi Pasteur INC. | $29.25 | 2021-2022 | |
| Daiichi Sankyo INC. | $27.61 | 2024 | Injectafer |
| Amarin Pharma, INC. | $27.54 | 2020 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $25.59 | 2022 | |
| Neurocrine Biosciences, INC. | $19.75 | 2023 | Ingrezza |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.07 | 2021 | |
| Abbott Laboratories | $14.46 | 2023 | Octrode |
| Inspire Medical Systems, INC. | $13.93 | 2025 | Inspire |
| Medtronic, INC. | $13.81 | 2022 | |
| Kaleo, INC. | $11.75 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Martin Glaves listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.